Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes
Open Access
- 25 March 2018
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 7 (5) , 331-341
Abstract
Reusing published models saves time; time to be used for informing decisions in drug development. In antihyperglycemic drug development, several published HbA1c models are available but selecting the appropriate model for a particular purpose is challenging. This study aims at helping selection by investigating four HbA1c models, specifically the ability to identify drug effects (shape, site of action, and power) and simulation properties. All models could identify glucose effect nonlinearities, although for detecting the site of action, a mechanistic glucose model was needed. Power was highest for models using mean plasma glucose to drive HbA1c formation. Insulin contribution to power varied greatly depending on the drug target; it was beneficial only if the drug target was insulin secretion. All investigated models showed good simulation properties. However, extrapolation with the mechanistic model beyond 12 weeks resulted in drug effect overprediction. This investigation aids drug development in decisions regarding model choice if reusing published HbA1c models.Keywords
Funding Information
- European Union Seventh Framework Programme (FP7/2007‐2013)
This publication has 32 references indexed in Scilit:
- Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic TreatmentsCPT: Pharmacometrics & Systems Pharmacology, 2013
- Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesThe Journal of Clinical Pharmacology, 2013
- The impact of mathematical modeling on the understanding of diabetes and related complicationsCPT: Pharmacometrics & Systems Pharmacology, 2013
- Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetesMetabolism, 2013
- Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeCPT: Pharmacometrics & Systems Pharmacology, 2013
- Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose‐Insulin ModelThe Journal of Clinical Pharmacology, 2012
- Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects ModelsThe AAPS Journal, 2012
- An Integrated Glucose‐Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 DiabeticsThe Journal of Clinical Pharmacology, 2007
- Standardization of Insulin Immunoassays: Report of the American Diabetes Association WorkgroupClinical Chemistry, 2007
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004